Verhoek, Andre http://orcid.org/0000-0003-3958-0033
Cheema, Parneet
Melosky, Barbara
Samson, Benoit
Shepherd, Frances A.
de Marinis, Filippo
John, Thomas
Wu, Yi-Long
Heeg, Bart
Van Dalfsen, Nadia
Bracke, Benjamin
Miranda, Miguel
Shaw, Simon
Moldaver, Daniel
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 30 January 2023
First Online: 22 February 2023
Declarations
:
: The study was funded by AstraZeneca. The sponsor was involved in the study design; in the collection, analysis, and interpretation of data; and in the writing of the report. Draft 1 was written by the first and last authors. Technical editing support was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (ExternalRef removed).
: Andre Verhoek reports funding from AstraZeneca to his employers (Cytel) for development of the model for the submitted work. Parneet Cheema reports consulting fees from AstraZeneca and Roche; honoraria from AstraZeneca, Bristol Myers Squibb, and Merck; advisory boards or committees for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and Takeda; invited speaker activities for AstraZeneca, Bristol Myers Squibb, and Merck; and advisory roles for Amgen, AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck, Novartis, Pfizer, and Roche. Barbara Melosky declares no competing interests. Benoit Samson reports advisory boards or committees for AstraZeneca, Bristol Myers Squibb, Merck, Pfizer, and Takeda. Frances A. Shepherd reports stock options from AstraZeneca. Filippo de Marinis reports consulting fees from AstraZeneca, Bristol Myers Squibb, MSD, and Roche AG, and advisory boards or committees for AstraZeneca, Bristol Myers Squibb, MSD, and Roche AG. Thomas John reports consulting fees from AstraZeneca, Bristol Myers Squibb, Ignyta, Merck & Co., MSD, Pfizer Inc., Roche AG, Specialised Therapeutics, and Takeda Pharmaceutical, and advisory boards and committees for AstraZeneca, Bristol Myers Squibb, Ignyta, Merck & Co., MSD, Pfizer Inc., Roche AG, Specialised Therapeutics, and Takeda Pharmaceutical, outside the submitted work. Yi-Long Wu reports grants or contracts from AstraZeneca, Beigen, Boehringer Ingelheim, Bristol Myers Squibb, Hengrui, and Roche; advisory boards or committees for AstraZeneca, Boehringer Ingelheim, Novartis, and Takeda; and honoraria received from AstraZeneca, Beigen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Pfizer, Roche, and Sanofi, outside the submitted work. Bart Heeg reports funding from AstraZeneca to his employers (Cytel) for development of the model for the submitted work. Nadia Van Dalfsen reports funding from AstraZeneca to her employers (Cytel) for development of the model for the submitted work. Benjamin Bracke reports employment and holds stock options from AstraZeneca. Miguel Miranda reports employment and holds stock from AstraZeneca, outside the submitted work. Simon Shaw reports employment and holds stocks from AstraZeneca. Daniel Moldaver reports employment from AstraZeneca and holds stock/stock options from AstraZeneca, outside the submitted work.
: Provision of standard data underlying the findings described in this article may be obtained in accordance with AstraZeneca’s data sharing policy described atExternalRef removed. The code for the model is not available publicly.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualization: AV, BM, FdM, Y-LW, BH, NVD, SS, DM. Methodology: AV, BH, NVD, BB, MM, SS, DM. Software: AV, NVD, DM. Validation: PC, BS, BH, BB, MM, DM. Formal analysis: AV, BM, FdM, BH, NVD, BB, DM. Investigation: BM, DM. Resources: FAS, DM. Data curation: FdM, BH, DM. Writing—original draft: AV, DM. Writing—reviewing and editing: AV, PC, BM, BS, FAS, FdM, TJ, Y-LW, BH, NVD, BB, MM, DM. Visualization: AV, BM, DM. Supervision: BM, TJ, BH, BB, SS, DM. Project administration: SS. Funding acquisition: SS.